VERTEX PHARMACEUTICALS INC / MA Income Taxes Paid
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Income Taxes Paid of $501.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for the quarter ending 2026-06-30 was $419.20M, a 18.33% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for the quarter ending 2026-03-31 was $82.30M, a 55.37% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for the quarter ending 2025-12-31 was $389.40M, a 43.27% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for the quarter ending 2025-09-30 was $479.60M, a 72.21% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for fiscal 2025 was $1.57B, a 44.78% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for fiscal 2024 was $1.08B, a 35.49% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for fiscal 2023 was $1.68B, a 58.56% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA income taxes paid, net for fiscal 2022 was $1.06B, a 122.09% increase from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 3 month as first filed | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 6 month as first filed | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 9 month as first filed | Income Taxes Paid, Net 12 month | Income Taxes Paid, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $419.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $501.50M 10-Q · filed 2026-08-04 | $890.90M derived: sum of 3 quarters · filed 2026-08-04 | $1.37B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $82.30M 10-Q · filed 2026-05-05 | $471.70M derived: sum of 2 quarters · filed 2026-05-05 | $951.30M derived: sum of 3 quarters · filed 2026-05-05 | $1.46B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $389.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $869.00M derived: sum of 2 quarters · filed 2026-02-13 | $1.38B derived: sum of 3 quarters · filed 2026-08-04 | $1.57B 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $479.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $992.90M derived: sum of 2 quarters · filed 2026-08-04 | $1.18B 10-Q · filed 2025-11-04 | $1.45B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $513.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $697.70M 10-Q · filed 2026-08-04 | $969.50M derived: sum of 3 quarters · filed 2026-08-04 | $1.25B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $184.40M 10-Q · filed 2026-05-05 | $456.20M derived: sum of 2 quarters · filed 2026-05-05 | $734.70M derived: sum of 3 quarters · filed 2026-05-05 | $1.23B derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $271.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $550.30M derived: sum of 2 quarters · filed 2026-02-13 | $1.05B derived: sum of 3 quarters · filed 2026-02-13 | $1.08B 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $278.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $775.50M derived: sum of 2 quarters · filed 2025-11-04 | $810.30M 10-Q · filed 2025-11-04 | $1.57B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $497.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $531.80M 10-Q · filed 2025-08-05 | $1.29B derived: sum of 3 quarters · filed 2026-02-13 | $1.59B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $34.80M 10-Q · filed 2025-05-06 | $793.00M derived: sum of 2 quarters · filed 2026-02-13 | $1.09B derived: sum of 3 quarters · filed 2026-02-13 | $1.59B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $758.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $1.06B derived: sum of 2 quarters · filed 2026-02-13 | $1.56B derived: sum of 3 quarters · filed 2026-02-13 | $1.68B 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $300.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $798.80M derived: sum of 2 quarters · filed 2024-11-05 | $919.10M 10-Q · filed 2024-11-05 | $1.14B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $498.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $618.70M 10-Q · filed 2024-08-02 | $836.40M derived: sum of 3 quarters · filed 2025-02-13 | $1.20B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $120.30M 10-Q · filed 2024-05-07 | $338.00M derived: sum of 2 quarters · filed 2025-02-13 | $699.80M derived: sum of 3 quarters · filed 2025-02-13 | $1.09B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $217.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $579.50M derived: sum of 2 quarters · filed 2025-02-13 | $972.80M derived: sum of 3 quarters · filed 2025-02-13 | $1.06B 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $361.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $755.10M derived: sum of 2 quarters · filed 2023-11-07 | $840.10M 10-Q · filed 2023-11-07 | $934.90M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $393.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $478.30M 10-Q · filed 2023-08-02 | $573.10M derived: sum of 3 quarters · filed 2024-02-15 | $720.20M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $85.00M 10-Q · filed 2023-05-02 | $179.80M derived: sum of 2 quarters · filed 2024-02-15 | $326.90M derived: sum of 3 quarters · filed 2024-02-15 | $550.60M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $94.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $241.90M derived: sum of 2 quarters · filed 2024-02-15 | $465.60M derived: sum of 3 quarters · filed 2024-02-15 | $476.30M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $147.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $370.80M derived: sum of 2 quarters · filed 2022-10-28 | $381.50M 10-Q · filed 2022-10-28 | $381.53M 10-Q · filed 2021-11-03 | $491.62M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | $223.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $234.40M 10-Q · filed 2022-08-05 | $234.40M 10-Q · filed 2021-07-30 | $344.52M derived: sum of 3 quarters · filed 2023-02-10 | $389.39M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | $10.70M 10-Q · filed 2022-05-06 | $10.69M 10-Q · filed 2021-04-30 | $120.82M derived: sum of 2 quarters · filed 2023-02-10 | $165.69M derived: sum of 3 quarters · filed 2023-02-10 | $196.66M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $110.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $154.99M derived: sum of 2 quarters · filed 2023-02-10 | $185.96M derived: sum of 3 quarters · filed 2023-02-10 | $191.80M 10-K · filed 2023-02-10 | $191.78M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $44.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $75.84M derived: sum of 2 quarters · filed 2021-11-03 | $81.68M 10-Q · filed 2021-11-03 | $83.55M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $30.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $36.81M 10-Q · filed 2021-07-30 | $38.67M derived: sum of 3 quarters · filed 2022-02-09 | $50.61M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $5.84M 10-Q · filed 2021-04-30 | $7.71M derived: sum of 2 quarters · filed 2022-02-09 | $19.64M derived: sum of 3 quarters · filed 2022-02-09 | $28.71M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $13.80M derived: sum of 2 quarters · filed 2022-02-09 | $22.86M derived: sum of 3 quarters · filed 2022-02-09 | $24.70M 10-K · filed 2022-02-09 | $24.73M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $21.00M derived: sum of 2 quarters · filed 2020-10-30 | $22.84M 10-Q · filed 2020-10-30 | $24.92M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $10.90M 10-Q · filed 2020-07-31 | $12.99M derived: sum of 3 quarters · filed 2021-02-11 | $16.23M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $1.83M 10-Q · filed 2020-05-01 | $3.92M derived: sum of 2 quarters · filed 2021-02-11 | $7.17M derived: sum of 3 quarters · filed 2021-02-11 | $12.34M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $5.33M derived: sum of 2 quarters · filed 2021-02-11 | $10.51M derived: sum of 3 quarters · filed 2021-02-11 | $12.40M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $8.42M derived: sum of 2 quarters · filed 2019-10-31 | $10.32M 10-Q · filed 2019-10-31 | $12.58M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $5.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $7.07M 10-Q · filed 2019-08-01 | $9.33M derived: sum of 3 quarters · filed 2020-02-13 | $11.27M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $1.90M 10-Q · filed 2019-05-01 | $4.16M derived: sum of 2 quarters · filed 2020-02-13 | $6.09M derived: sum of 3 quarters · filed 2020-02-13 | $7.15M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $4.20M derived: sum of 2 quarters · filed 2020-02-13 | $5.25M derived: sum of 3 quarters · filed 2020-02-13 | $6.41M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $2.99M derived: sum of 2 quarters · filed 2018-10-25 | $4.15M 10-Q · filed 2018-10-25 | -$42.00K derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $2.22M 10-Q · filed 2018-07-26 | -$1.98M derived: sum of 3 quarters · filed 2019-02-13 | -$1.60M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-03-31 | $1.16M 10-Q · filed 2018-04-27 | -$3.03M derived: sum of 2 quarters · filed 2019-02-13 | -$2.65M derived: sum of 3 quarters · filed 2019-02-13 | -$2.00M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2016-12-31 | -$4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$3.82M derived: sum of 2 quarters · filed 2019-02-13 | -$3.16M derived: sum of 3 quarters · filed 2019-02-13 | -$2.58M 10-K · filed 2019-02-13 | ||||
| 2016-09-30 | $380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $1.04M derived: sum of 2 quarters · filed 2017-10-30 | $1.62M 10-Q · filed 2017-10-30 | $4.68M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | $656.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $1.24M 10-Q · filed 2017-07-28 | $4.30M derived: sum of 3 quarters · filed 2018-02-15 | |||||
| 2016-03-31 | $581.00K 10-Q · filed 2017-04-28 | $3.65M derived: sum of 2 quarters · filed 2018-02-15 | ||||||
| 2015-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $1.81M 10-K · filed 2018-02-15 | ||||||
| 2015-09-30 | -$1.26M 10-Q · filed 2016-10-31 | |||||||
| 2014-12-31 | $1.21M 10-K · filed 2017-02-23 | |||||||
| 2013-12-31 | $2.84M 10-K · filed 2016-02-16 | |||||||
| 2013-03-31 | $1.54M 10-Q · filed 2013-05-08 | |||||||
| 2012-12-31 | $9.32M 10-K · filed 2015-02-13 | |||||||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | $0.00 10-K · filed 2014-02-11 | |||||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |